Aptose Biosciences Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Stock-based Compensation (Tables)

Note 11 - Stock-based Compensation (Tables)

3 Months Ended

Mar. 31, 2022

Notes Tables

Share-Based Payment Arrangement, Option, Activity [Table Text Block]

Option numbers are in (000’s)
						Three months ended March 31, 2022
		Options				Weighted average exercise price				Weighted average remaining contractual life (years)

Outstanding, beginning of period			15,112			$	4.61
Granted			3,870				1.34
Exercised			(14	)			1.08
Forfeited			(349	)			4.77
Outstanding, end of the period			18,619				3.97				7.0
Exercisable, end of the period			10,736				4.68				5.5
Vested and expected to vest, end of period			17,344				4.03				6.9

Option numbers are in (000’s)
						Three months ended March 31, 2021
		Options				Weighted average exercise price				Weighted average remaining contractual life (years)

Outstanding, beginning of period			11,942			$	4.97
Granted			2,962				4.47
Exercised			(39	)			1.97
Forfeited			(703	)			5.67
Outstanding, end of the period			14,162				4.85				7.1
Exercisable, end of the period			7,887				4.59				5.95
Vested and expected to vest, end of period			13,220				4.83				6.99

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

		Three months ended March 31, 2022				Three months ended March 31, 2021

Risk-free interest rate			1.7	%			0.4	%
Expected dividend yield			-				-
Expected volatility			83.3	%			80.7	%
Expected life of options		5 years				5 years
Grant date fair value		$	0.89			$	2.85

Schedule of Share-based Payment Award, Options, Grants in Period [Table Text Block]

Option numbers are in (000’s)		Three months ended March 31, 2022				Three months ended March 31, 2021
		Number of options				Number of options
3 year vesting (50%-25%-25%)			425				430
4 year vesting (50%-16 2/3%-16 2/3%-16 2/3%)			3,445				2,532
Total stock options granted in the period			3,870				2,962

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

		Three months ended March 31, 2022				Three months ended March 31, 2021

Research and development		$	946			$	1,378
General and administrative			1,568				5,265
Total		$	2,514			$	6,643